Hem › Myelodysplastiska syndrom › Ohio
Kliniska studier för Myelodysplastiska syndrom i Ohio
22 studier för Myelodysplastiska syndrom söker deltagare vid platser i Ohio.
Städer i Ohio
Officiell studietext (engelska)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Ohio State University Comprehensive Cancer Center, Columbus
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Cleveland clinic OH, Cleveland
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 18 sep. 2026 · NCT07422480Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
RekryterarObservationsstudie
2 Months · Alla kön · Uppdaterad 16 sep. 2026 · NCT00900198Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 15 sep. 2026 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT03471260Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Ohio State University, The James Comprehensive Cancer, Columbus
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Ohio State University Comprehensive Cancer Center, Columbus
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 3 sep. 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- och 3 fler
RekryterarFas 1/2
Upp till ålder 22 · Alla kön · Uppdaterad 25 aug. 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Gabrail Cancer Center Research, Canton
- Cleveland Clinic - Cleveland, Cleveland
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 21 aug. 2026 · NCT06499285Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 10 aug. 2026 · NCT05308264A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, Canton
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 juni 2026 · NCT068478675-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
RekryterarTidig fas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 18 maj 2026 · NCT04187703A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 apr. 2026 · NCT04256317Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- Ohio State University Medical Center, Columbus
RekryterarFas 1
Ålder 18 till 65 · Alla kön · Uppdaterad 25 mars 2026 · NCT03533816A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- The Ohio State University Comprehensive Cancer Center, Columbus
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 24 mars 2026 · NCT04988555Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Cleveland Clinic Cancer Center, Cleveland
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 5 mars 2026 · NCT06543381HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekryterarFas 2
3 Months · Alla kön · Uppdaterad 12 nov. 2025 · NCT02143830SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 28 okt. 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2025 · NCT06501196HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
RekryterarObservationsstudie
Ålder 12 till 80 · Alla kön · Uppdaterad 28 aug. 2025 · NCT07145411Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.